Cover Image

Q-TWiST analysis of sacituzumab govitecan vs. chemotherapy in previously treated patients with HR+/HER2− metastatic breast cancer

In TROPiCS-02, sacituzumab govitecan (SG) demonstrated significantly longer overall survival and progression-free survival with improved quality of life vs. chemotherapy treatment of physician’s choice (TPC) in patients with HR+/HER2− metastatic breast cancer (mBC). The safety profile was consistent...

Full description

Saved in:
Bibliographic Details
Main Authors: Rugo, Hope S. (Author) , Bardia, Aditya (Author) , Schmid, Peter (Author) , Tolaney, Sara M. (Author) , Dasgupta, Anandaroop (Author) , Kaushik, Ankita (Author) , Verret, Wendy (Author) , Gosset, Marine (Author) , Brufsky, Adam (Author) , Cortés, Javier (Author) , Marmé, Frederik (Author)
Format: Article (Journal)
Language:English
Published: 15 March 2025
In: Current oncology
Year: 2025, Volume: 32, Issue: 3, Pages: 1-10
ISSN:1718-7729
DOI:10.3390/curroncol32030169
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/curroncol32030169
Verlag, kostenfrei, Volltext: https://www.mdpi.com/1718-7729/32/3/169
Get full text
Author Notes:Hope S. Rugo, Aditya Bardia, Peter Schmid, Sara M. Tolaney, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Marine Gosset, Adam Brufsky, Javier Cortés and Frederik Marmé
Description
Summary:In TROPiCS-02, sacituzumab govitecan (SG) demonstrated significantly longer overall survival and progression-free survival with improved quality of life vs. chemotherapy treatment of physician’s choice (TPC) in patients with HR+/HER2− metastatic breast cancer (mBC). The safety profile was consistent with previous studies of SG. We assessed the benefit--risk profile of SG vs. TPC by integrating patient preferences with clinical benefits using Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis in this study population. Survival time was partitioned into three health states: TOX (grade ≥3 treatment-emergent adverse events [TEAEs] after randomization/before disease progression), REL (disease progression until death or end of follow-up), and TWiST (time without progression or grade ≥3 TEAEs). Health state utility weights were obtained from the published literature. The established threshold for clinically important Q-TWiST gain is 10%. SG demonstrated significantly improved Q-TWiST vs. TPC (mean 9.7 vs. 8.1 months; difference 1.6 months; 95% CI, 0.5-2.7; p = 0.0067), which increased with longer follow-up. Relative Q-TWiST improvement met the threshold for clinical importance at 10.8%. Time in TOX was numerically higher with SG than TPC, and the difference stabilized over time. Q-TWiST supports a positive benefit-risk profile for SG over TPC in patients with pretreated HR+/HER2− mBC.
Item Description:Gesehen am 02.07.2025
Physical Description:Online Resource
ISSN:1718-7729
DOI:10.3390/curroncol32030169

Similar Items